GlaxoSmithKline to provide unique child gene therapy

GlaxoSmithKline to provide unique child gene therapy


The world's first gene therapy treatment for children to be given regulatory approval has been authorised for sale by a British firm. GlaxoSmithKline was given permission by the European Commission to provide Strimvelis - the first ex-vivo stem cell gene therapy to treat patients with a very rare disease called ADA-SCID .



from Biotech News